In details, in two post hoc analyses of the COMPARZ study and the METEOR and CABOSUN trials, respectively, PD-L1 expression on tumor cells was associated with shorter survival in mRCC patients, irrespectively of the type of targeted therapy received (28, 29). Here, CD274 is linked to neoplasm.